niacin has been researched along with Diabetes Mellitus, Adult-Onset in 102 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the effects of low-dose niacin extended-release (niacin-ER) combined with simvastatin (SV) in the treatment of patients with mixed dyslipidemia who have not normalized their lipid profile with statin therapy alone." | 9.14 | Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. ( Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV, 2010) |
| "To assess the efficacy and safety of ezetimibe/simvastatin (E/S) plus extended-release niacin (N) in hyperlipidaemic patients with diabetes mellitus (DM), metabolic syndrome (MetS) without DM (MetS/non-DM) or neither (non-DM/non-MetS)." | 9.14 | Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. ( Fazio, S; Guyton, JR; Lin, J; Shah, A; Tershakovec, AM; Tomassini, JE, 2010) |
| "We assumed that adding the niacin to the medication in patients with type 2 diabetes would reduce dyslipidemia and achieve target lipid levels." | 5.41 | The efficacy of niacin supplementation in type 2 diabetes patients: Study protocol of a randomized controlled trial. ( Wang, S; Yan, X, 2021) |
| "The aim of this study was to evaluate the effects of low-dose niacin extended-release (niacin-ER) combined with simvastatin (SV) in the treatment of patients with mixed dyslipidemia who have not normalized their lipid profile with statin therapy alone." | 5.14 | Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad. ( Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV, 2010) |
| "To assess the efficacy and safety of ezetimibe/simvastatin (E/S) plus extended-release niacin (N) in hyperlipidaemic patients with diabetes mellitus (DM), metabolic syndrome (MetS) without DM (MetS/non-DM) or neither (non-DM/non-MetS)." | 5.14 | Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. ( Fazio, S; Guyton, JR; Lin, J; Shah, A; Tershakovec, AM; Tomassini, JE, 2010) |
| "To investigate the effect of low-dose aspirin administered in the morning or evening on the rate of discontinuation of prolonged-release nicotinic acid (Niaspan) due to flushing in patients at elevated cardiovascular risk." | 5.13 | Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk. ( Alves, JD; Darioli, R; Hostalek, U; Steinhagen-Thiessen, E; Vogt, A, 2008) |
| "Low-dose niacin is a promising addition to hydroxymethylglutaryl-coenzyme A reductase inhibitor therapy in the treatment of hypercholesterolemia in patients with diabetes mellitus." | 5.08 | Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. ( Fonseca, VA; Gardner, SF; Granberry, MC; Marx, MA; Skelton, DR; White, LM, 1997) |
| "The prevalences of diabetes and adult obesity were highly correlated with per capita consumption of niacin, thiamin and riboflavin with a 26-and 10-year lag, respectively (R2 = 0." | 3.76 | B-vitamin consumption and the prevalence of diabetes and obesity among the US adults: population based ecological study. ( Li, D; Liu, QG; Sun, WP; Zhou, SS; Zhou, YM, 2010) |
| "Fenofibrate was a cost-effective either as monotherapy or combined with a statin compared to statin or fenofibrate monotherapy." | 3.01 | A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus. ( Abushanab, D; Ademi, Z; Al-Badriyeh, D; Bailey, C; Jaam, M; Liew, D; Marquina, C, 2023) |
| "In statin-treated men with type 2 diabetes mellitus, ERN decreased plasma Lp(a) concentrations by decreasing the production of apo(a) and Lp(a)-apoB-100." | 2.80 | Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. ( Barrett, PH; Chan, DC; Hamilton, SJ; Marcovina, SM; McCormick, SP; Ooi, EM; Pang, J; Tenneti, VS; Watts, GF, 2015) |
| "Twelve men with type 2 diabetes mellitus were recruited for a randomized, crossover design trial." | 2.79 | Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus. ( Barrett, PH; Chan, DC; Hamilton, SJ; Pang, J; Tenneti, VS; Watts, GF, 2014) |
| "placebo on the incidence of new onset type 2 diabetes mellitus (T2DM) and cardiovascular event rates in patients with normal and impaired fasting glucose (IFG)." | 2.78 | Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. ( Canner, PL; Maccubbin, D; Sazonov, V; Sisk, CM, 2013) |
| "HDL from patients with type 2 diabetes mellitus and metabolic syndrome has substantially impaired endothelial-protective effects compared with HDL from healthy subjects." | 2.75 | Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. ( Bahlmann, FH; Bahr, MJ; Besler, C; Doerries, C; Drexler, H; Flemmer, S; Haller, H; Heinemann, M; Heinrich, K; Horváth, T; Landmesser, U; Manes, C; Markowski, A; Meyer, M; Mueller, M; Rohrer, L; Sorrentino, SA; von Eckardstein, A, 2010) |
| "Diabetic dyslipidemia is characterized by high triglyceride levels; low high-density lipoprotein cholesterol levels; small, dense low-density lipoprotein particles; and high free fatty acid levels." | 2.70 | Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. ( Buse, JB; Fitz-Patrick, D; Ganda, OP; Grundy, SM; Kendall, DM; McGovern, ME; Robertson, DD; Rosenson, RS; Sheehan, JP; Tulloch, BR; Vega, GL, 2002) |
| " Our analysis also showed the absence of publication bias and any dose-response relations between niacin and effect size." | 2.52 | Effect of niacin on lipids and glucose in patients with type 2 diabetes: A meta-analysis of randomized, controlled clinical trials. ( Ding, Y; Li, Y; Wen, A, 2015) |
| "In the metabolic syndrome and type 2 diabetes, excess energy intake on the background of genetic predisposition and lifestyle factors leads to the dysregulation of fatty acid metabolism and acquired insulin resistance." | 2.48 | Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes. ( Matikainen, N; Taskinen, MR, 2012) |
| "Low HDL-C levels are common in type 2 diabetes but are not currently recommended as a target for treatment because of the lack of definitive cardiovascular outcome studies supporting this goal, and because of the difficulty in raising HDL-C." | 2.46 | Management of dyslipidemia in people with type 2 diabetes mellitus. ( Dunn, FL, 2010) |
| "It is generally accepted that type 2 diabetes is the result of gene-environmental interaction." | 2.46 | [Chronic nicotinamide overload and type 2 diabetes]. ( Li, D; Liu, XX; Lun, YZ; Sun, WP; Zhou, SS; Zhou, YM, 2010) |
| "The lipid profile of type 2 diabetes mellitus is characterized by increased triglycerides (TGs), decreased high-density lipoprotein cholesterol (HDL-C), increased very low density lipoproteins (VLDLs), and small, dense low-density lipoprotein particles, the combination of which is highly atherogenic." | 2.45 | Managing diabetic dyslipidemia: beyond statin therapy. ( Gadi, R; Neeli, H; Rader, DJ, 2009) |
| "Patients with type 2 diabetes have a marked increase in the risk of premature coronary heart disease (CHD)." | 2.44 | Dyslipidaemia in diabetic patients: time for a rethink. ( Shepherd, J, 2007) |
| "Both diabetes and metabolic syndrome are associated with a clustering of cardiovascular risk factors." | 2.43 | Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. ( Betteridge, J; Shepherd, J; Van Gaal, L, 2005) |
| "The metabolic syndrome and type 2 diabetes mellitus are both becoming more prevalent, and both increase the risk of cardiovascular disease." | 2.43 | Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. ( Nesto, RW, 2005) |
| "Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism." | 2.42 | Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. ( Cottrell, DA; Falko, JM; Marshall, BJ, 2003) |
| "Treatment of the dyslipidemia associated with type 2 diabetes and FCHL with a combination of a statin and a thiazolidinedione or niacin offers the most comprehensive modality to correct the various lipid abnormalities." | 2.42 | Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. ( Ayyobi, AF; Brunzell, JD, 2003) |
| "Patients with NIDDM are unable to increase their glucose oxidation normally in response to insulin to meet the energy demands of the body." | 2.38 | Insulin action and substrate competition. ( Ferrannini, E; Groop, LC, 1993) |
| "Prediabetes is a metabolic condition associated with gut microbiome composition, although mechanisms remain elusive." | 1.91 | A Fecal Metabolite Signature of Impaired Fasting Glucose: Results From Two Independent Population-Based Cohorts. ( Asnicar, F; Bagnardi, V; Baleanu, AF; Bell, JT; Breuninger, T; Christiansen, C; Dong, Q; Falchi, M; Franks, PW; Gieger, C; Grallert, H; Linseisen, J; Louca, P; Menni, C; Michelotti, GA; Nogal, A; Peters, A; Segata, N; Spector, TD; Tettamanzi, F; Valdes, AM; Visconti, A; Wawro, N; Wong, K, 2023) |
| "60 patients with DPN and type 2 diabetes mellitus with a disease duration of 6 to 25 years were examined and treated." | 1.56 | [The effect of complex use of nicotinic acid electrophoresis and air bubble baths on microcirculation in patients with diabetic polyneuropathy]. ( Kolbakhova, SN; Konchugova, TV; Kulchitskaya, DB; Tsoi, AV; Turova, EA, 2020) |
| "Niacin is a popular nutritional supplement known to reduce the risk of cardiovascular diseases by enhancing high-density lipoprotein levels." | 1.42 | Involvement of the Niacin Receptor GPR109a in the LocalControl of Glucose Uptake in Small Intestine of Type 2Diabetic Mice. ( Chan, LK; Leung, PS; Wong, TP, 2015) |
| "Patients with type 2 diabetes and hyperlipidemia were included for review if they received the combination of pioglitazone at doses ≥ 15 mg/day and extended-release niacin (Niaspan) at doses ≥ 1000 mg/day for ≥6 months." | 1.39 | The effect of pioglitazone and extended-release niacin on HDL-cholesterol in diabetes patients in a real-world setting. ( Bhargava, A; Gleason, S; Johnson, JF; Vaughan, AG; Yarlagadda, KV, 2013) |
| "Patients with type 2 diabetes have increased expression of cell adhesion molecules (CAMs)." | 1.37 | Niacin results in reduced monocyte adhesion in patients with type 2 diabetes mellitus. ( Dong, X; Jauhar, N; Lim, SC; Pek, LT; Sum, CF; Tavintharan, S; Woon, K, 2011) |
| "In subjects with prevalent type 2 diabetes, homozygous carriers of the most common SIRT1 haplotype, 1, had 1." | 1.35 | SIRT1 genetic variation and mortality in type 2 diabetes: interaction with smoking and dietary niacin. ( Dehghan, A; Hofman, A; Pols, HA; Rivadeneira, F; Sijbrands, EJ; Uitterlinden, AG; van Duijn, CM; van Leeuwen, JP; van Meurs, JB; Witteman, JC; Zillikens, MC, 2009) |
| "Niacin has recently been shown to increase serum total concentrations of the adipocyte-derived protein adiponectin." | 1.35 | Increased total and high-molecular weight adiponectin after extended-release niacin. ( Brunson, BL; Grandjean, PW; Judd, RL; Plaisance, EP, 2008) |
| " The primary endpoint was the safety and tolerability of prolonged-release nicotinic acid, with special regard to treatment-related adverse drug reactions (ADRs)." | 1.34 | Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients. ( Assmann, G; Birjmohun, RS; Hostalek, U; Kastelein, JJ; Poldermans, D; Stroes, ES, 2007) |
| "Ten patients with NIDDM, CAD, and severe LV dysfunction (mean ejection fraction, 29." | 1.31 | Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction. ( Beanlands, RS; deKemp, RA; Ruddy, TD; Vitale, GD; Williams, K, 2001) |
| "Patients received Niaspan 1000, 1500, or 2000 mg/day (median daily dosage 1000 mg)." | 1.31 | Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes. ( Addesse, E; Bakst, G; Busch, RS; Hamilton, RA; Kane, MP, 2001) |
| "Glycerol, which was present in the infused lipid (272 mmol/l) did not affect ISR." | 1.30 | Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. ( Boden, G; Chen, X, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.96) | 18.7374 |
| 1990's | 12 (11.76) | 18.2507 |
| 2000's | 41 (40.20) | 29.6817 |
| 2010's | 40 (39.22) | 24.3611 |
| 2020's | 7 (6.86) | 2.80 |
| Authors | Studies |
|---|---|
| Abushanab, D | 1 |
| Al-Badriyeh, D | 1 |
| Marquina, C | 1 |
| Bailey, C | 1 |
| Jaam, M | 1 |
| Liew, D | 1 |
| Ademi, Z | 1 |
| Xia, J | 1 |
| Yu, J | 1 |
| Xu, H | 1 |
| Zhou, Y | 1 |
| Li, H | 1 |
| Yin, S | 1 |
| Xu, D | 1 |
| Wang, Y | 1 |
| Xia, H | 1 |
| Liao, W | 1 |
| Wang, S | 2 |
| Sun, G | 1 |
| Nogal, A | 1 |
| Tettamanzi, F | 1 |
| Dong, Q | 2 |
| Louca, P | 1 |
| Visconti, A | 1 |
| Christiansen, C | 1 |
| Breuninger, T | 1 |
| Linseisen, J | 1 |
| Grallert, H | 1 |
| Wawro, N | 1 |
| Asnicar, F | 1 |
| Wong, K | 1 |
| Baleanu, AF | 1 |
| Michelotti, GA | 1 |
| Segata, N | 1 |
| Falchi, M | 1 |
| Peters, A | 1 |
| Franks, PW | 1 |
| Bagnardi, V | 1 |
| Spector, TD | 1 |
| Bell, JT | 1 |
| Gieger, C | 1 |
| Valdes, AM | 1 |
| Menni, C | 1 |
| Massimino, E | 1 |
| Izzo, A | 1 |
| Castaldo, C | 1 |
| Amoroso, AP | 1 |
| Rivellese, AA | 1 |
| Capaldo, B | 1 |
| Della Pepa, G | 1 |
| Kulchitskaya, DB | 1 |
| Turova, EA | 1 |
| Konchugova, TV | 1 |
| Kolbakhova, SN | 1 |
| Tsoi, AV | 1 |
| Xiang, D | 1 |
| Zhang, Q | 1 |
| Wang, YT | 1 |
| Yan, X | 1 |
| Skolnik, N | 1 |
| Jaffa, FM | 1 |
| Kalyani, RR | 1 |
| Johnson, E | 1 |
| Shubrook, JH | 1 |
| Fangmann, D | 1 |
| Theismann, EM | 1 |
| Türk, K | 1 |
| Schulte, DM | 1 |
| Relling, I | 1 |
| Hartmann, K | 1 |
| Keppler, JK | 1 |
| Knipp, JR | 1 |
| Rehman, A | 1 |
| Heinsen, FA | 1 |
| Franke, A | 1 |
| Lenk, L | 1 |
| Freitag-Wolf, S | 1 |
| Appel, E | 1 |
| Gorb, S | 1 |
| Brenner, C | 1 |
| Seegert, D | 1 |
| Waetzig, GH | 1 |
| Rosenstiel, P | 1 |
| Schreiber, S | 1 |
| Schwarz, K | 1 |
| Laudes, M | 1 |
| Xie, YD | 1 |
| Chen, ZZ | 1 |
| Li, N | 1 |
| Lu, WF | 1 |
| Xu, YH | 1 |
| Lin, YY | 1 |
| Shao, LH | 1 |
| Wang, QT | 1 |
| Guo, LY | 1 |
| Gao, YQ | 1 |
| Yang, GD | 1 |
| Li, YP | 1 |
| Bian, XL | 1 |
| Wierzbicki, AS | 1 |
| Sazonov, V | 2 |
| Maccubbin, D | 4 |
| Sisk, CM | 3 |
| Canner, PL | 1 |
| Reiner, Z | 1 |
| Christou, GA | 1 |
| Rizos, EC | 1 |
| Mpechlioulis, A | 1 |
| Penzo, C | 1 |
| Pacchioni, A | 1 |
| Nikas, DN | 1 |
| Bhargava, A | 1 |
| Gleason, S | 1 |
| Vaughan, AG | 1 |
| Johnson, JF | 1 |
| Yarlagadda, KV | 1 |
| Stevens, BD | 1 |
| Litchfield, J | 1 |
| Pfefferkorn, JA | 1 |
| Atkinson, K | 1 |
| Perreault, C | 1 |
| Amor, P | 1 |
| Bahnck, K | 1 |
| Berliner, MA | 1 |
| Calloway, J | 1 |
| Carlo, A | 1 |
| Derksen, DR | 1 |
| Filipski, KJ | 1 |
| Gumkowski, M | 1 |
| Jassal, C | 1 |
| MacDougall, M | 1 |
| Murphy, B | 1 |
| Nkansah, P | 1 |
| Pettersen, J | 1 |
| Rotter, C | 1 |
| Zhang, Y | 1 |
| Pang, J | 3 |
| Chan, DC | 3 |
| Hamilton, SJ | 4 |
| Tenneti, VS | 3 |
| Watts, GF | 4 |
| Barrett, PH | 3 |
| Manoria, PC | 1 |
| Chopra, HK | 1 |
| Parashar, SK | 1 |
| Dutta, AL | 1 |
| Pinto, B | 1 |
| Mullasari, A | 1 |
| Prajapati, S | 1 |
| Hafiane, A | 1 |
| Kellett, S | 1 |
| Genest, J | 1 |
| Ding, Y | 1 |
| Li, Y | 1 |
| Wen, A | 1 |
| Masana, L | 2 |
| Cabré, A | 1 |
| Heras, M | 2 |
| Amigó, N | 2 |
| Correig, X | 2 |
| Martínez-Hervás, S | 2 |
| Real, JT | 1 |
| Ascaso, JF | 1 |
| Quesada, H | 1 |
| Julve, J | 1 |
| Palomer, X | 1 |
| Vázquez-Carrera, M | 1 |
| Girona, J | 1 |
| Plana, N | 2 |
| Blanco-Vaca, F | 1 |
| Bays, HE | 2 |
| Brinton, EA | 2 |
| Triscari, J | 2 |
| Chen, E | 2 |
| MacLean, AA | 2 |
| Gibson, KL | 1 |
| Ruck, RA | 2 |
| Johnson-Levonas, AO | 2 |
| O'Neill, EA | 2 |
| Mitchel, YB | 2 |
| Wong, TP | 1 |
| Chan, LK | 1 |
| Leung, PS | 1 |
| Ooi, EM | 1 |
| McCormick, SP | 1 |
| Marcovina, SM | 1 |
| Misra, A | 1 |
| Bhardwaj, S | 1 |
| Mallol, R | 1 |
| Blanco Vaca, F | 1 |
| Escolà-Gil, JC | 1 |
| Yanes, Ó | 1 |
| Brudi, P | 1 |
| Collins, PD | 1 |
| Sattar, N | 1 |
| Nichols, GA | 1 |
| Reynolds, K | 1 |
| Olufade, T | 1 |
| Kimes, TM | 1 |
| O'Keeffe-Rosetti, M | 1 |
| Sapp, DS | 1 |
| Anzalone, D | 1 |
| Fortmann, SP | 1 |
| Alves, JD | 1 |
| Steinhagen-Thiessen, E | 1 |
| Darioli, R | 1 |
| Hostalek, U | 2 |
| Vogt, A | 1 |
| Davidson, M | 1 |
| Jones, PH | 1 |
| McNamara, DB | 1 |
| Murthy, SN | 1 |
| Fonseca, AN | 1 |
| Desouza, CV | 1 |
| Kadowitz, PJ | 1 |
| Fonseca, VA | 2 |
| Zillikens, MC | 1 |
| van Meurs, JB | 1 |
| Sijbrands, EJ | 1 |
| Rivadeneira, F | 1 |
| Dehghan, A | 1 |
| van Leeuwen, JP | 1 |
| Hofman, A | 1 |
| van Duijn, CM | 1 |
| Witteman, JC | 1 |
| Uitterlinden, AG | 1 |
| Pols, HA | 1 |
| Tan, KC | 1 |
| Neeli, H | 1 |
| Gadi, R | 1 |
| Rader, DJ | 1 |
| Merkel, M | 1 |
| Ginsberg, HN | 1 |
| Maccallum, PR | 1 |
| Bitzur, R | 1 |
| Cohen, H | 1 |
| Kamari, Y | 1 |
| Shaish, A | 1 |
| Harats, D | 1 |
| Libby, A | 1 |
| Meier, J | 1 |
| Lopez, J | 1 |
| Swislocki, AL | 1 |
| Siegel, D | 1 |
| Sorrentino, SA | 1 |
| Besler, C | 1 |
| Rohrer, L | 1 |
| Meyer, M | 1 |
| Heinrich, K | 1 |
| Bahlmann, FH | 1 |
| Mueller, M | 1 |
| Horváth, T | 1 |
| Doerries, C | 1 |
| Heinemann, M | 1 |
| Flemmer, S | 1 |
| Markowski, A | 1 |
| Manes, C | 1 |
| Bahr, MJ | 1 |
| Haller, H | 1 |
| von Eckardstein, A | 1 |
| Drexler, H | 1 |
| Landmesser, U | 1 |
| Zhou, SS | 2 |
| Li, D | 2 |
| Zhou, YM | 2 |
| Sun, WP | 2 |
| Liu, XX | 1 |
| Lun, YZ | 1 |
| Dunn, FL | 1 |
| Pan, J | 1 |
| Shilian, P | 1 |
| Ishida, B | 1 |
| Wu, X | 1 |
| Kane, JP | 1 |
| Malloy, MJ | 1 |
| Charles, MA | 1 |
| Yoshinari, O | 1 |
| Igarashi, K | 1 |
| Jialal, I | 1 |
| Amess, W | 1 |
| Kaur, M | 1 |
| Chew, GT | 1 |
| Davis, TM | 1 |
| Wallach, I | 1 |
| Jaitly, N | 1 |
| Lilien, R | 1 |
| Fazio, S | 1 |
| Guyton, JR | 1 |
| Lin, J | 2 |
| Tomassini, JE | 1 |
| Shah, A | 2 |
| Tershakovec, AM | 2 |
| Salgado, BJ | 1 |
| Salgado, JV | 1 |
| Dos Santos, AM | 1 |
| Casulari, LA | 1 |
| Liu, QG | 1 |
| Ambegaonkar, BM | 1 |
| Wentworth, C | 1 |
| Allen, C | 1 |
| Tavintharan, S | 1 |
| Woon, K | 1 |
| Pek, LT | 1 |
| Jauhar, N | 1 |
| Dong, X | 1 |
| Lim, SC | 1 |
| Sum, CF | 1 |
| Bays, H | 1 |
| Giezek, H | 1 |
| McKenney, JM | 1 |
| Matikainen, N | 1 |
| Taskinen, MR | 1 |
| Grundy, SM | 2 |
| Vega, GL | 1 |
| McGovern, ME | 1 |
| Tulloch, BR | 1 |
| Kendall, DM | 1 |
| Fitz-Patrick, D | 1 |
| Ganda, OP | 1 |
| Rosenson, RS | 2 |
| Buse, JB | 1 |
| Robertson, DD | 1 |
| Sheehan, JP | 1 |
| Tomono, S | 1 |
| Ohyama, Y | 1 |
| Uchiyama, T | 1 |
| Packard, C | 1 |
| Olsson, AG | 1 |
| Mikhail, N | 1 |
| Cottrell, DA | 1 |
| Marshall, BJ | 1 |
| Falko, JM | 2 |
| Ayyobi, AF | 1 |
| Brunzell, JD | 1 |
| Hawkins, M | 2 |
| Tonelli, J | 2 |
| Kishore, P | 2 |
| Stein, D | 1 |
| Ragucci, E | 1 |
| Gitig, A | 1 |
| Reddy, K | 2 |
| Wild, S | 1 |
| Byrne, CD | 1 |
| Meyers, CD | 1 |
| Kamanna, VS | 1 |
| Kashyap, ML | 1 |
| Rassman, J | 1 |
| Gupta, S | 1 |
| März, W | 1 |
| Shepherd, J | 2 |
| Betteridge, J | 1 |
| Van Gaal, L | 1 |
| Carpentier, AC | 1 |
| Frisch, F | 1 |
| Cyr, D | 1 |
| Généreux, P | 1 |
| Patterson, BW | 1 |
| Giguère, R | 1 |
| Baillargeon, JP | 1 |
| Rasouli, N | 1 |
| Hale, T | 1 |
| Kahn, SE | 2 |
| Spencer, HJ | 1 |
| Elbein, SC | 1 |
| Nesto, RW | 1 |
| Koppaka, S | 1 |
| Fratila, C | 1 |
| Bose, A | 1 |
| Lee, DE | 1 |
| Rink, C | 1 |
| Roy, S | 1 |
| Khanna, S | 1 |
| Rink, T | 1 |
| Bagchi, D | 1 |
| Sen, CK | 1 |
| Tenenbaum, A | 1 |
| Fisman, EZ | 1 |
| Motro, M | 1 |
| Adler, Y | 1 |
| Tahrani, AA | 1 |
| Rana, JS | 1 |
| Nieuwdorp, M | 1 |
| Jukema, JW | 1 |
| Kastelein, JJ | 2 |
| Birjmohun, RS | 1 |
| Poldermans, D | 1 |
| Stroes, ES | 1 |
| Assmann, G | 1 |
| Moser, RJ | 1 |
| Meis, SB | 1 |
| Caulin-Glaser, T | 1 |
| Plaisance, EP | 1 |
| Grandjean, PW | 1 |
| Brunson, BL | 1 |
| Judd, RL | 1 |
| Cannon, CP | 1 |
| Tsalamandris, C | 1 |
| Panagiotopoulos, S | 1 |
| Sinha, A | 1 |
| Cooper, ME | 1 |
| Jerums, G | 1 |
| Groop, LC | 1 |
| Ferrannini, E | 1 |
| Saloranta, C | 1 |
| Groop, L | 1 |
| Thomas, VL | 1 |
| Gropper, SS | 1 |
| Gardner, SF | 1 |
| Marx, MA | 1 |
| White, LM | 1 |
| Granberry, MC | 1 |
| Skelton, DR | 1 |
| Boden, G | 2 |
| Chen, X | 2 |
| Iqbal, N | 1 |
| Gotto, AM | 1 |
| Worm, D | 1 |
| Vinten, J | 1 |
| Vaag, A | 1 |
| Henriksen, JE | 1 |
| Beck-Nielsen, H | 1 |
| Vitale, GD | 1 |
| deKemp, RA | 1 |
| Ruddy, TD | 1 |
| Williams, K | 1 |
| Beanlands, RS | 1 |
| Kane, MP | 1 |
| Hamilton, RA | 1 |
| Addesse, E | 1 |
| Busch, RS | 1 |
| Bakst, G | 1 |
| Foley, JE | 1 |
| Johnston, P | 1 |
| Hollenbeck, C | 1 |
| Sheu, W | 1 |
| Chen, YD | 1 |
| Reaven, GM | 1 |
| Garg, A | 1 |
| Porte, D | 1 |
| Berova, N | 1 |
| Lazarova, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo Controlled 36 Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients With Type 2 Diabetes[NCT00485758] | Phase 3 | 796 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Post-prandial Effects of Extra Virgin Olive Oil on Endothelial Function in Adults at Risk for Type 2 Diabetes: A Randomized Crossover Controlled Trial[NCT04025281] | 20 participants (Actual) | Interventional | 2019-07-09 | Completed | |||
| The Impact of Consumption of Eggs in the Context of Plant-Based Diets on[NCT04316429] | 35 participants (Actual) | Interventional | 2020-06-09 | Completed | |||
| Randomized Clinical Trial to Study the Effect of Extended Release Niacin on Endothelial Function, Oxidative Stress and Endothelial Progenitor Cells in Patients With the Metabolic Syndrome.[NCT00346970] | Phase 4 | 32 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| "A Multicenter, Randomized, Double-Blind, Factorial Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Coadministered MK0524B Tablets in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia"[NCT00269217] | Phase 3 | 1,400 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia[NCT00269204] | Phase 3 | 1,620 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.[NCT00479388] | Phase 3 | 1,216 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Randomized, Double-blind, Placebo-controlled Trial of Niaspan® in Patients With Overt Diabetic Nephropathy and Moderate Renal Impairment[NCT00108485] | Phase 3 | 9 participants (Actual) | Interventional | 2005-04-30 | Terminated (stopped due to Unable to recruit sufficient study subjects) | ||
| Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol[NCT01131299] | Phase 2 | 103 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
After 12 weeks of treatment, to assess the increase of high-density lipoprotein cholesterol in patients with Type 2 diabetes when compared to placebo (NCT00485758)
Timeframe: Baseline and 12 Weeks
| Intervention | Percent change at Wk 12 compared to Bl (Least Squares Mean) |
|---|---|
| Extended Release Niacin/Laropiprant | 25.4 |
| Placebo | 2.2 |
After 12 Weeks of treatment, to assess the reduction of low-density lipoprotein cholesterol in patients with Type 2 diabetes when compared to placebo (NCT00485758)
Timeframe: Baseline and 12 Weeks
| Intervention | Percent change at Wk 12 compared to Bl (Least Squares Mean) |
|---|---|
| Extended Release Niacin/Laropiprant | -15.8 |
| Placebo | 2.1 |
after 12 weeks of treatment, to assess the reduction of triglycerides in patients with Type 2 diabetes when compared to placebo (NCT00485758)
Timeframe: Baseline and 12 Weeks
| Intervention | Percent change at Wk 12 compared to Bl (Median) |
|---|---|
| Extended Release Niacin/Laropiprant | -22.2 |
| Placebo | 2.3 |
(NCT00479388)
Timeframe: Baseline and 12 Weeks
| Intervention | Percent (Least Squares Mean) |
|---|---|
| ER Niacin/Laropiprant + Run-in Statin | 15.8 |
| Run-in Statin Dose Doubled | 0.2 |
(NCT00479388)
Timeframe: Baseline and 12 Weeks
| Intervention | Percent (Least Squares Mean) |
|---|---|
| ER Niacin/Laropiprant + Run-in Statin | -10.0 |
| Run-in Statin Dose Doubled | -5.5 |
(NCT00479388)
Timeframe: Baseline and 12 Weeks
| Intervention | Percent (Median) |
|---|---|
| ER Niacin/Laropiprant + Run-in Statin | -17.6 |
| Run-in Statin Dose Doubled | -4.0 |
(NCT00108485)
Timeframe: Baseline, 1 year
| Intervention | mg/dL (Number) |
|---|---|
| Extended Release Niacin | 42 |
| Placebo | 63 |
LIRI was measured at the end of each study arm (a-CD or placebo). a-CD (2g) was taken orally three times a day for 12-14 weeks. Placebo (2 tablets) was taken orally for 12-14 weeks. There was a one-week washout period between each arm. (NCT01131299)
Timeframe: 24-28 weeks
| Intervention | percentage (Mean) |
|---|---|
| a-CD | 1.4 |
| Placebo | 1.6 |
Serum glucose levels was measured at the end of each study arm (a-CD or placebo). a-CD (2g) was taken orally three times a day for 12-14 weeks. Placebo (2 tablets) was taken orally for 12-14 weeks. There was a one-week washout period between each arm. (NCT01131299)
Timeframe: 24-28 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| a-CD | 87 |
| Placebo | 88 |
Small LDL particle numbers were measured at the end of each study arm (a-CD or placebo). a-CD (2g) was taken orally three times a day for 12-14 weeks. Placebo (2 tablets) was taken orally for 12-14 weeks. There was a one-week washout period between each arm. (NCT01131299)
Timeframe: 24-28 weeks
| Intervention | nmol/L (Mean) |
|---|---|
| a-CD | 365 |
| Placebo | 405 |
Total cholesterol levels were measured at the end of each study arm (a-CD or placebo). a-CD (2g) was taken orally three times a day for 12-14 weeks. Placebo (2 tablets) was taken orally for 12-14 weeks. There was a one-week washout period between each arm. (NCT01131299)
Timeframe: 24-28 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| a-CD | 180 |
| Placebo | 180 |
39 reviews available for niacin and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; | 2023 |
Comparative effects of vitamin and mineral supplements in the management of type 2 diabetes in primary care: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Cholesterol; Chromium; Diabetes Mellitus, Type 2; Dietary Supplements; Humans; Micronutrients; Miner | 2023 |
Effectiveness of niacin supplementation for patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dietary Supplements; Humans; Lipids; Niacin; Randomized Co | 2020 |
Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Topics: Antibodies, Monoclonal; Anticholesteremic Agents; Apolipoprotein A-I; Benzimidazoles; Cardiovascular | 2013 |
Confronting the residual cardiovascular risk beyond statins: the role of fibrates, omega-3 fatty acids, or niacin, in diabetic patients.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fatty Acids, Omega-3; Fibric Acids; Humans; Niac | 2014 |
The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.
Topics: Atherosclerosis; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Management; | 2013 |
Treatment options for low high-density lipoproteins.
Topics: Atherosclerosis; Biomarkers; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Diabeti | 2014 |
Effect of niacin on lipids and glucose in patients with type 2 diabetes: A meta-analysis of randomized, controlled clinical trials.
Topics: Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Databases, Factual; Diabetes Mellitus, Type 2; Fa | 2015 |
Glycaemic Effects of Non-statin Lipid-Lowering Therapies.
Topics: Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabeti | 2016 |
A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, | 2008 |
Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug | 2008 |
Animal models of catheter-induced intimal hyperplasia in type 1 and type 2 diabetes and the effects of pharmacologic intervention.
Topics: Animals; Biguanides; Catheterization; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Di | 2009 |
Reverse cholesterol transport in type 2 diabetes mellitus.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein A-I; ATP-Binding Cassette Transporters; Biological | 2009 |
Managing diabetic dyslipidemia: beyond statin therapy.
Topics: Cholesterol, HDL; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angi | 2009 |
[Diabetic dyslipoproteinemia: beyond LDL].
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chy | 2009 |
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dysli | 2009 |
Triglycerides and HDL cholesterol: stars or second leads in diabetes?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications | 2009 |
Triglycerides and HDL cholesterol: stars or second leads in diabetes?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications | 2009 |
Triglycerides and HDL cholesterol: stars or second leads in diabetes?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications | 2009 |
Triglycerides and HDL cholesterol: stars or second leads in diabetes?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications | 2009 |
[Chronic nicotinamide overload and type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Diet; Food, Fortified; Humans; Niacin; Niacinamide | 2010 |
Management of dyslipidemia in people with type 2 diabetes mellitus.
Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ez | 2010 |
Management of hypertriglyceridemia in the diabetic patient.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; H | 2010 |
Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fibric Acids; | 2012 |
[Insulin resistance induced by drugs, inflammation and stress].
Topics: Adrenergic beta-Antagonists; Benzothiadiazines; Contraceptives, Oral, Hormonal; Cyclosporins; Diabet | 2002 |
Management of hypercholesterolaemia in the patient with diabetes.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, T | 2002 |
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2003 |
Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.
Topics: Abdomen; Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 2003 |
Niacin therapy in atherosclerosis.
Topics: Anti-Inflammatory Agents; Arteriosclerosis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hu | 2004 |
The metabolic syndrome: modify root causes, treat risk factors.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Education, Medical, Continuing; Humans; Hydroxymethylgl | 2005 |
Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Europe; Humans; Hyperlipidemias; Hypolipidemic A | 2005 |
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diet; Drug T | 2005 |
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxy | 2006 |
Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Va | 2007 |
Dyslipidaemia in diabetic patients: time for a rethink.
Topics: Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hu | 2007 |
Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; | 2005 |
Combination therapy in the management of mixed dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Routes; Dr | 2008 |
Insulin action and substrate competition.
Topics: Animals; Binding, Competitive; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gluconeogenesi | 1993 |
Interactions between glucose and FFA metabolism in man.
Topics: Animals; Biological Transport; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Human | 1996 |
Triglyceride as a risk factor for coronary artery disease.
Topics: Biomarkers; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, | 1998 |
Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Fatty Acids; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Models, B | 1992 |
Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta-cell dysfunction?
Topics: Amyloid; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Insulin; Insulin Resistance; Insulinoma; | 1989 |
23 trials available for niacin and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
The efficacy of niacin supplementation in type 2 diabetes patients: Study protocol of a randomized controlled trial.
Topics: Adult; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dietary Supplements; Double-Blind Met | 2021 |
Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose.
Topics: Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Meth | 2013 |
Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-O | 2014 |
Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
Topics: Adult; Aged; Antioxidants; Biomarkers; Cholesterol, HDL; Cross-Sectional Studies; Diabetes Mellitus, | 2015 |
Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
Topics: Aged; Biomarkers; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blin | 2015 |
Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus.
Topics: Aged; Apolipoprotein B-100; Apolipoproteins A; Biomarkers; Cross-Over Studies; Delayed-Action Prepar | 2015 |
Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes.
Topics: Aged; Apolipoprotein B-48; Cardiovascular Diseases; Cross-Over Studies; Delayed-Action Preparations; | 2016 |
Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein B-100; Blood Glucose; Cholesterol, HDL; Cholesterol, | 2016 |
Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Dela | 2008 |
Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy.
Topics: Aged; Animals; Cells, Cultured; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diabetic Ang | 2010 |
Effect of niacin on preβ-1 high-density lipoprotein levels in diabetes.
Topics: Aged; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Hig | 2011 |
Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients.
Topics: Aged; Arterioles; Compliance; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combin | 2010 |
Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellit | 2010 |
Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.
Topics: Aged; Aspirin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidem | 2010 |
Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Chy | 2012 |
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, HDL; Chole | 2002 |
Effects of short-term experimental insulin resistance and family history of diabetes on pancreatic beta-cell function in nondiabetic individuals.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Tolerance Test | 2005 |
Time-dependent effects of free fatty acids on glucose effectiveness in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gluco | 2006 |
Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients.
Topics: Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug | 1994 |
Effect of chromium nicotinic acid supplementation on selected cardiovascular disease risk factors.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholest | 1996 |
Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 1; D | 1997 |
The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in type 2 diabetic patients.
Topics: Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; | 2000 |
Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus.
Topics: Aged; Analysis of Variance; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical | 1990 |
40 other studies available for niacin and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
A Fecal Metabolite Signature of Impaired Fasting Glucose: Results From Two Independent Population-Based Cohorts.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Glucose; Humans; Niacin; Prediabetic State | 2023 |
Dietary micronutrient adequacies and adherence to the Mediterranean diet in a population of older adults with type 2 diabetes: A cross-sectional study.
Topics: Aged; Calcium; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diet, Mediterranean; Female; Huma | 2023 |
[The effect of complex use of nicotinic acid electrophoresis and air bubble baths on microcirculation in patients with diabetic polyneuropathy].
Topics: Balneology; Baths; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Electrophoresis; Humans; Microc | 2020 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; | 2017 |
Targeted Microbiome Intervention by Microencapsulated Delayed-Release Niacin Beneficially Affects Insulin Sensitivity in Humans.
Topics: Adult; Case-Control Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Compoundin | 2018 |
Hydroxytyrosol nicotinate, a new multifunctional hypolipidemic and hypoglycemic agent.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hy | 2018 |
Sugar, sugar.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucose Intolerance; Humans; Hypolipidemic Agents; | 2013 |
The effect of pioglitazone and extended-release niacin on HDL-cholesterol in diabetes patients in a real-world setting.
Topics: Analysis of Variance; Cholesterol, HDL; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug | 2013 |
Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia.
Topics: Allosteric Regulation; Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Drug Evaluation, Preclin | 2013 |
Involvement of the Niacin Receptor GPR109a in the LocalControl of Glucose Uptake in Small Intestine of Type 2Diabetic Mice.
Topics: Animals; Blood Glucose; Caco-2 Cells; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Respon | 2015 |
Management of the Metabolic Syndrome and the Obese Patient with Metabolic Disturbances: South Asian Perspective.
Topics: Adipose Tissue; Asia; Asian People; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Dietar | 2015 |
Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "Herniated" HDL, a common feature in diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Fenofibra | 2016 |
Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Cost-Benefit Analysis; Diabetes Mellitus, | 2017 |
SIRT1 genetic variation and mortality in type 2 diabetes: interaction with smoking and dietary niacin.
Topics: Aged; Aging; Cohort Studies; Cytoprotection; Diabetes Mellitus, Type 2; Dietary Supplements; Female; | 2009 |
The effect of body mass index on fasting blood glucose and development of diabetes mellitus after initiation of extended-release niacin.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Blood Glucose; Body Mass Index; Delayed-Action Pre | 2010 |
Anti-diabetic effect of trigonelline and nicotinic acid, on KK-A(y) mice.
Topics: Alkaloids; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Glucokinase; Glucose-6-Phosph | 2010 |
A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways.
Topics: Breast Neoplasms; Computational Biology; Databases, Factual; Diabetes Mellitus, Type 2; Drug-Related | 2010 |
B-vitamin consumption and the prevalence of diabetes and obesity among the US adults: population based ecological study.
Topics: Adult; Age Distribution; Aged; Centers for Disease Control and Prevention, U.S.; Diabetes Mellitus, | 2010 |
Association between extended-release niacin treatment and glycemic control in patients with type 2 diabetes mellitus: analysis of an administrative-claims database.
Topics: Adult; Aged; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Drug Therapy, Combinatio | 2011 |
Niacin results in reduced monocyte adhesion in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Cardiovascular Diseases; Cell Adhesion; Cell Adhesion Molecules; Cholesterol, HDL; Diab | 2011 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Clinical Trials, Phase III as | 2012 |
Niacin seems OK for people with diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Niacin | 2002 |
The use of niacin in diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemi | 2003 |
Contribution of elevated free fatty acid levels to the lack of glucose effectiveness in type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Emulsions; Fatty Acids, Nonesterified; Glucose | 2003 |
[HDL cholesterol as protective factor. Deficiency threatens the diabetic heart].
Topics: Cholesterol, HDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypo | 2003 |
The role of treatment to increase HDL-cholesterol and decrease triglyceride concentrations in prevention of coronary heart disease in Type 2 diabetes.
Topics: Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hy | 2004 |
[Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mell | 2005 |
On the suppression of plasma nonesterified fatty acids by insulin during enhanced intravascular lipolysis in humans.
Topics: Adult; Blood Glucose; Calorimetry, Indirect; Diabetes Mellitus, Type 2; Dose-Response Relationship, | 2005 |
Transcriptome of the subcutaneous adipose tissue in response to oral supplementation of type 2 Leprdb obese diabetic mice with niacin-bound chromium.
Topics: Adipose Tissue; Administration, Oral; Animals; Apoptosis Regulatory Proteins; Blood Glucose; Cholest | 2006 |
Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: another focus.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA R | 2006 |
Measure for measure--sugar or fats? Reconciling cardiovascular and diabetes risk with niacin therapy.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Lipoproteins; Metabolic Syndrome; Niacin | 2007 |
Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients.
Topics: Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2007 |
Increased total and high-molecular weight adiponectin after extended-release niacin.
Topics: Adiponectin; Adult; Body Composition; Body Weight; Cardiovascular Diseases; Delayed-Action Preparati | 2008 |
Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects.
Topics: 3-Hydroxybutyric Acid; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Emulsions; Fat Emulsions, Int | 1998 |
Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes.
Topics: 3-Hydroxybutyric Acid; Aged; C-Peptide; Diabetes Mellitus, Type 2; Fat Emulsions, Intravenous; Fatty | 1999 |
Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglucose F18; Glucose; Glucose | 2001 |
Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes.
Topics: Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hypolipidemic Agents; Male; M | 2001 |
Acute changes in plasma non-esterified fatty acid concentration do not change hepatic glucose production in people with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Glu | 1990 |
Nicotinic acid in NIDDM.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Lipids; Niacin | 1990 |
[Pellagra-like changes following glibenclamide treatment in a patient with diabetes mellitus and vitiligo].
Topics: Diabetes Mellitus, Type 2; Drug Eruptions; Female; Glyburide; Humans; Middle Aged; Pellagra; Vitilig | 1988 |